Navigation Links
Application of Hepatocyte Growth Factor - New Hope for Many Conditions
Date:12/2/2013

BEIJING, Dec. 2, 2013 /PRNewswire/ -- ReLife International Medical Center researches hepatocyte growth factors. HGF is a paracrine cellular growth, motility and morphogenic factor secreted by mesenchymal cells. By acting as a multi-functional cytokine, HGF is being applied in treatments for not only hepatic conditions but also many other diseases in nowadays due to its angionenic, anti-fibrotic and antiapoptosis actions. [1, 2]

Ischemic diseases  HFG can stimulate the migration, proliferation and neovascularization of vascular endothelial cells. In addition, HGF is capable of protecting the nerves cell by increasing neuronal survival and axonal regeneration. HGF has proven to be effective in gene therapy for limb ischemia conditions and myocardial ischemia. Decreasing of ulceration area and pain relief have been shown in patients with lower limb ischemia conditions after being treated with HGF. Combination of mesenchymal stem cells - MSCs with adenovirus carrying HGF can promote neovascularization in chronic ischemic myocardium, inhibit apoptosis and improve the cardiac functions.

Diabetes  HFG can inhibit the apoptosis of endothelial cells under hyperglycemic environment and promote the repair process of vascular endothelial cells, which is an ideal treatment for diabetic vascular complications. On the other hand, HGF can inhibit the fibrosis of renal interstitium of Diabetic Nephropathy. It can also promote MSCs to differentiate into islet cells in stem cell therapy.

Others  HFG is able to relieve neuron hypoxia injuries and promote neural stem cells to differentiate into neuronal cells. HGF can also protect human pulmonary microvascular endothelial cells and promote the repair of damage resulting from a pulmonary injury, etc.

With its multi-functional characteristics, HGF might have a bright future in the medical field.

[1] Azuma J, Taniyama Y, Takeya Y, et al. Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther, 2006, 13: 1206--1213

[2] Jayasankar V, Woo Y J, Pirolli T J, et al. Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure. J Card Surg, 2005, 20: 93--101


'/>"/>
SOURCE ReLife International Medical Center
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Applications due in December for Photonics Innovation Village
2. Mesenchymal Stem Cells - Advances & Applications 2013
3. Convey Computer to OEM Dell Servers to Accelerate Data Intensive Applications for Data Centers
4. Convey Computer Announces New Hybrid-Core Coprocessor to Accelerate Data-Intensive Applications
5. Biomarkers: Discovery Techniques and Applications - A Global Market Overview
6. Applications Due This Month for SPIE Startup Challenge at Photonics West 2014
7. MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of MCT-485, a Noncoding miRNA for Cancer Treatment
8. Advances for Food Safety, Energy, Security and More on the Program for SPIE Micro+Nano Materials, Devices, and Applications
9. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
10. CIRTEMO to Launch Multivariate Optical Element Platform for Neuroscience Applications
11. Tunisia Hosts First African Summer School on Optics and Applications to Sustainable Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
Breaking Biology News(10 mins):